Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 3/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152730 | 0.81 | JAK2 (0.36) | CNR2PGR | |
| SCHEMBL6152556 | 0.81 | TNKS (0.33) | IGF1RTNKSCNR2 | |
| SCHEMBL6153035 | 0.77 | ALDH1A1 (0.39) | MAPK1 | |
| SCHEMBL6152057 | 0.68 | MEN1 (0.41) | — | |
| SCHEMBL5779413 | 0.68 | BRD4 (0.34) | HDAC6MAPK1 | |
| SCHEMBL5777360 | 0.61 | RAB9A (0.35) | MAPK1 | |
| SCHEMBL5775523 | 0.61 | KDM4E (0.35) | HDAC6MAPK1 | |
| SCHEMBL5775180 | 0.61 | HCRTR1 (0.31) | — | |
| SCHEMBL23519606 | 0.61 | IDH1 (0.41) | HDAC6 | |
| SCHEMBL29878486 | 0.61 | IDH1 (0.41) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943181-B2 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2005-09-13 | — | — | US | claimed |
| EP-1406610-B1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-01-26 | — | — | EP | claimed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | claimed |
| EP-1406610-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004016-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| US-6943181-B2 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2005-09-13 | — | — | US | disclosed |
| EP-1551832-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1281703-B1 | Process for the preparation of 5-alkoxy-oxazoles as well as of pyridoxines | BASF AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| EP-1406610-B1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004031185-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| EP-1406610-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1281703-A1 | Process for the preparation of 5-alkoxy-oxazoles as well as of pyridoxines | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2003004016-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | BACE1, MYC, APP | GRM5 1055/4885MAOB 1790/4885CYP11B2 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.